BridgeMD
New treatment option for Smoking
Official title A Study of Brenipatide in Adults Who Quit Smoking Cigarettes and Want to Avoid Relapse
ClinicalTrials.gov ID: NCT07223840
What this study is testing
What is Brenipatide?
Brenipatide is an investigational medicine, given as an injection under the skin, being studied as a potential treatment for smoking.
Also referred to as LY3537031.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study evaluates the efficacy and safety of brenipatide when compared to placebo for reducing the risk of relapse to cigarette smoking in adults who have recently quit. Study participation will last approximately 34 weeks with up to 17 study visits, which includes a 2-week screening period, 24-week treatment period, 8-week safety follow-up period.
- Phase 2: a mid-size study of how well it works
- You might receive a placebo (an inactive treatment) instead of the study drug.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- Have recently quit smoking and are motivated to stay quit from smoking
- Are reliable and willing to make themselves available for the duration of the study and attend required study visits and are willing and able to...
You likely can't join if
- Have evidence of any substance use disorder within the past 180 days prior to screening, except mild alcohol use disorder, mild cannabis use...
- Have answered "yes" to either Question 4 or Question 5 on the "Suicidal Ideation" portion of the C-SSRS and the ideation occurred within the past 6...
- Have severe chronic obstructive pulmonary disease, or any other clinically severe respiratory condition that in the investigator's opinion may pose a...
- Have participated in a clinical study and have received active treatment, or unknown if they received active treatment, within 90 days or 5...
The study team makes the final eligibility decision.
Where it's taking place
- Rogers, Arkansas, United States
- DeLand, Florida, United States
- Hollywood, Florida, United States
- Maitland, Florida, United States
- Miami, Florida, United States
- Woodstock, Georgia, United States
- Dearborn, Michigan, United States
- St Louis, Missouri, United States
- Las Vegas, Nevada, United States
- Rochester, New York, United States
- North Charleston, South Carolina, United States
- Sioux Falls, South Dakota, United States
- Dallas, Texas, United States
- Houston, Texas, United States
- Newport News, Virginia, United States
- Redmond, Washington, United States
- Beijing, China
- Chengdu, China
- Chongqing, China
- Hangzhou, China
+ 6 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Rogers, Arkansas, United States; DeLand, Florida, United States; Hollywood, Florida, United States; Maitland, Florida, United States; Miami, Florida, United States; Woodstock, Georgia, United States and 20 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.